MIT researchers have developed a computational model called IM3PACT to predict the human body’s response to different glucose-responsive insulin (GRI) designs. Researchers created this model to analyze a discontinued GRI clinical trial that showed limited effectiveness in humans despite success in animal studies.
The IM3PACT model revealed differences in the behavior of a mannose receptor in humans, which could be the reason why the trial failed. The model demonstrated lower responsiveness in humans than in preclinical models, highlighting the need for improved therapeutic design tools in glucose-responsive insulin development.
Ref: Yang J, Yang S, Gong X, et al. In Silico Investigation of the Clinical Translatability of Competitive Clearance Glucose-Responsive Insulins. ACS pharmacology & translational science. Published online September 18, 2023. doi:https://doi.org/10.1021/acsptsci.3c00095